Do analysts recommend RGC or ATAI?

Atai Beckley has a consensus target price of $16.00, indicating a potential upside of 283.69%. Given Atai Beckley's stronger consensus rating and higher probable upside, analysts clearly believe Atai Beckley is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Atai Beckley 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.91

Which has stronger valuation & earnings, RGC or ATAI?

Regencell Bioscience has higher earnings, but lower revenue than Atai Beckley. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Atai Beckley $4.09M 375.37 -$660.05M -$2.23 N/A

Does the media refer more to RGC or ATAI?

In the previous week, Regencell Bioscience had 17 more articles in the media than Atai Beckley. MarketBeat recorded 18 mentions for Regencell Bioscience and 1 mentions for Atai Beckley. Regencell Bioscience's average media sentiment score of 0.00 beat Atai Beckley's score of 0.00 indicating that Regencell Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 15 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Atai Beckley 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ATAI or COGT?

In the previous week, Cogent Biosciences had 1 more articles in the media than Atai Beckley. MarketBeat recorded 2 mentions for Cogent Biosciences and 1 mentions for Atai Beckley. Cogent Biosciences' average media sentiment score of 0.36 beat Atai Beckley's score of 0.00 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Beckley 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cogent Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BLTE or ATAI more profitable?

Belite Bio has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Belite Bio's return on equity of -13.14% beat Atai Beckley's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -13.14% -12.88% Atai Beckley -19,019.44% -89.79% -63.58%

Does the media favor BLTE or ATAI?

In the previous week, Belite Bio had 2 more articles in the media than Atai Beckley. MarketBeat recorded 3 mentions for Belite Bio and 1 mentions for Atai Beckley. Belite Bio's average media sentiment score of 0.42 beat Atai Beckley's score of 0.00 indicating that Belite Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atai Beckley 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SRRK or ATAI more profitable?

Scholar Rock has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Atai Beckley's return on equity of -89.79% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% Atai Beckley -19,019.44% -89.79% -63.58%

Does the media favor SRRK or ATAI?

In the previous week, Scholar Rock had 1 more articles in the media than Atai Beckley. MarketBeat recorded 2 mentions for Scholar Rock and 1 mentions for Atai Beckley. Scholar Rock's average media sentiment score of 1.15 beat Atai Beckley's score of 0.00 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atai Beckley 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ATAI or APGE?

In the previous week, Apogee Therapeutics had 39 more articles in the media than Atai Beckley. MarketBeat recorded 40 mentions for Apogee Therapeutics and 1 mentions for Atai Beckley. Apogee Therapeutics' average media sentiment score of 0.14 beat Atai Beckley's score of 0.00 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Beckley 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Apogee Therapeutics 10 Very Positive mention(s) 6 Positive mention(s) 15 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Atai Beckley (ATAI) Competitors

$4.17 +0.07 (+1.71%)

Closing price 06/24/2026 04:00 PM Eastern

Extended Trading

$4.21 +0.04 (+0.96%)

As of 08:24 AM Eastern

Compare

ATAI vs. RGC, COGT, BLTE, SRRK, and APGE

Should you buy Atai Beckley stock or one of its competitors? MarketBeat compares Atai Beckley with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atai Beckley include Regencell Bioscience (RGC), Cogent Biosciences (COGT), Belite Bio (BLTE), Scholar Rock (SRRK), and Apogee Therapeutics (APGE). These companies are all part of the "pharmaceutical products" industry.

How does Atai Beckley compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Atai Beckley (NASDAQ:ATAI) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Regencell Bioscience has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market.

In the previous week, Regencell Bioscience had 17 more articles in the media than Atai Beckley. MarketBeat recorded 18 mentions for Regencell Bioscience and 1 mentions for Atai Beckley. Regencell Bioscience's average media sentiment score of 0.00 beat Atai Beckley's score of 0.00 indicating that Regencell Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	15 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 28.4% of Atai Beckley shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by insiders. Comparatively, 26.8% of Atai Beckley shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Regencell Bioscience has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Regencell Bioscience's return on equity of 0.00% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Atai Beckley	-19,019.44%	-89.79%	-63.58%

Atai Beckley has a consensus target price of $16.00, indicating a potential upside of 283.69%. Given Atai Beckley's stronger consensus rating and higher probable upside, analysts clearly believe Atai Beckley is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Regencell Bioscience has higher earnings, but lower revenue than Atai Beckley.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Atai Beckley	$4.09M	375.37	-$660.05M	-$2.23	N/A

Summary

Regencell Bioscience and Atai Beckley tied by winning 7 of the 14 factors compared between the two stocks.

How does Atai Beckley compare to Cogent Biosciences?

Atai Beckley (NASDAQ:ATAI) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

In the previous week, Cogent Biosciences had 1 more articles in the media than Atai Beckley. MarketBeat recorded 2 mentions for Cogent Biosciences and 1 mentions for Atai Beckley. Cogent Biosciences' average media sentiment score of 0.36 beat Atai Beckley's score of 0.00 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cogent Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

28.4% of Atai Beckley shares are owned by institutional investors. 26.8% of Atai Beckley shares are owned by company insiders. Comparatively, 6.6% of Cogent Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cogent Biosciences has lower revenue, but higher earnings than Atai Beckley. Cogent Biosciences is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	375.37	-$660.05M	-$2.23	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Atai Beckley currently has a consensus target price of $16.00, indicating a potential upside of 283.69%. Cogent Biosciences has a consensus target price of $43.73, indicating a potential upside of 16.51%. Given Atai Beckley's stronger consensus rating and higher possible upside, analysts plainly believe Atai Beckley is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Cogent Biosciences has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Atai Beckley's return on equity of -89.79% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
Cogent Biosciences	N/A	-104.27%	-54.64%

Atai Beckley has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

Summary

Atai Beckley beats Cogent Biosciences on 8 of the 15 factors compared between the two stocks.

How does Atai Beckley compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Atai Beckley (NASDAQ:ATAI) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 28.4% of Atai Beckley shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 26.8% of Atai Beckley shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Belite Bio currently has a consensus price target of $203.00, suggesting a potential upside of 34.64%. Atai Beckley has a consensus price target of $16.00, suggesting a potential upside of 283.69%. Given Atai Beckley's stronger consensus rating and higher possible upside, analysts clearly believe Atai Beckley is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Belite Bio has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Belite Bio's return on equity of -13.14% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Atai Beckley	-19,019.44%	-89.79%	-63.58%

Belite Bio has higher earnings, but lower revenue than Atai Beckley. Belite Bio is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
Atai Beckley	$4.09M	375.37	-$660.05M	-$2.23	N/A

Belite Bio has a beta of -1.24, suggesting that its stock price is 224% less volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market.

In the previous week, Belite Bio had 2 more articles in the media than Atai Beckley. MarketBeat recorded 3 mentions for Belite Bio and 1 mentions for Atai Beckley. Belite Bio's average media sentiment score of 0.42 beat Atai Beckley's score of 0.00 indicating that Belite Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Atai Beckley beats Belite Bio on 10 of the 16 factors compared between the two stocks.

How does Atai Beckley compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Atai Beckley (NASDAQ:ATAI) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 28.4% of Atai Beckley shares are held by institutional investors. 13.3% of Scholar Rock shares are held by insiders. Comparatively, 26.8% of Atai Beckley shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Scholar Rock has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Atai Beckley's return on equity of -89.79% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Atai Beckley	-19,019.44%	-89.79%	-63.58%

Scholar Rock has higher earnings, but lower revenue than Atai Beckley. Scholar Rock is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Atai Beckley	$4.09M	375.37	-$660.05M	-$2.23	N/A

Scholar Rock has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market.

In the previous week, Scholar Rock had 1 more articles in the media than Atai Beckley. MarketBeat recorded 2 mentions for Scholar Rock and 1 mentions for Atai Beckley. Scholar Rock's average media sentiment score of 1.15 beat Atai Beckley's score of 0.00 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Scholar Rock currently has a consensus price target of $56.00, suggesting a potential upside of 7.01%. Atai Beckley has a consensus price target of $16.00, suggesting a potential upside of 283.69%. Given Atai Beckley's higher probable upside, analysts plainly believe Atai Beckley is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Summary

Scholar Rock and Atai Beckley tied by winning 8 of the 16 factors compared between the two stocks.

How does Atai Beckley compare to Apogee Therapeutics?

Atai Beckley (NASDAQ:ATAI) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

Atai Beckley has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

28.4% of Atai Beckley shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 26.8% of Atai Beckley shares are held by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Apogee Therapeutics has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Apogee Therapeutics' return on equity of -32.64% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
Apogee Therapeutics	N/A	-32.64%	-31.25%

Atai Beckley currently has a consensus target price of $16.00, suggesting a potential upside of 283.69%. Apogee Therapeutics has a consensus target price of $121.25, suggesting a potential downside of 8.62%. Given Atai Beckley's stronger consensus rating and higher probable upside, equities analysts clearly believe Atai Beckley is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24

Apogee Therapeutics has lower revenue, but higher earnings than Atai Beckley. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	375.37	-$660.05M	-$2.23	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

In the previous week, Apogee Therapeutics had 39 more articles in the media than Atai Beckley. MarketBeat recorded 40 mentions for Apogee Therapeutics and 1 mentions for Atai Beckley. Apogee Therapeutics' average media sentiment score of 0.14 beat Atai Beckley's score of 0.00 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Apogee Therapeutics	10 Very Positive mention(s)	6 Positive mention(s)	15 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Atai Beckley beats Apogee Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Atai Beckley News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATAI vs. The Competition

Export

Metric	Atai Beckley	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.51B	$5.78B	$6.74B	$12.32B
Dividend Yield	N/A	1.54%	2.68%	5.88%
P/E Ratio	-1.87	37.32	25.13	23.95
Price / Sales	375.37	23.55	533.99	107.90
Price / Cash	N/A	17.26	45.29	53.76
Price / Book	6.04	3.34	10.78	6.41
Net Income	-$660.05M	$218.81M	$3.56B	$337.14M
7 Day Performance	2.71%	3.93%	0.96%	-1.07%
1 Month Performance	-3.47%	5.35%	0.77%	0.48%
1 Year Performance	89.55%	20.94%	30.24%	28.42%

Atai Beckley Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATAI Atai Beckley	3.398 of 5 stars	$4.17 +1.7%	$16.00 +283.7%	+97.6%	$1.51B	$4.09M	N/A	80
RGC Regencell Bioscience	0.52 of 5 stars	$10.51 -12.5%	N/A	-62.7%	$5.94B	N/A	N/A	10	Gap Down High Trading Volume
COGT Cogent Biosciences	1.7805 of 5 stars	$35.84 +3.8%	$43.73 +22.0%	+418.4%	$5.90B	N/A	N/A	80
BLTE Belite Bio	3.2604 of 5 stars	$147.07 +0.7%	$203.00 +38.0%	+152.6%	$5.86B	N/A	N/A	10	Insider Trade
SRRK Scholar Rock	2.063 of 5 stars	$49.19 +3.9%	$56.00 +13.8%	+56.6%	$5.67B	N/A	N/A	140	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATAI) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atai Beckley (ATAI) Competitors

ATAI vs. RGC, COGT, BLTE, SRRK, and APGE

How does Atai Beckley compare to Regencell Bioscience?

Summary

How does Atai Beckley compare to Cogent Biosciences?

Summary

How does Atai Beckley compare to Belite Bio?

Summary

How does Atai Beckley compare to Scholar Rock?

Summary

How does Atai Beckley compare to Apogee Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI vs. The Competition

Atai Beckley Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atai Beckley (ATAI) Competitors

ATAI vs. RGC, COGT, BLTE, SRRK, and APGE

How does Atai Beckley compare to Regencell Bioscience?

Which has more volatility and risk, RGC or ATAI?

Does the media refer more to RGC or ATAI?

Do institutionals and insiders have more ownership in RGC or ATAI?

Is RGC or ATAI more profitable?

Do analysts recommend RGC or ATAI?

Which has stronger valuation & earnings, RGC or ATAI?

Summary

How does Atai Beckley compare to Cogent Biosciences?

Does the media prefer ATAI or COGT?

Do institutionals & insiders believe in ATAI or COGT?

Which has higher valuation and earnings, ATAI or COGT?

Do analysts prefer ATAI or COGT?

Is ATAI or COGT more profitable?

Which has more volatility and risk, ATAI or COGT?

Summary

How does Atai Beckley compare to Belite Bio?

Do institutionals and insiders hold more shares of BLTE or ATAI?

Do analysts rate BLTE or ATAI?

Is BLTE or ATAI more profitable?

Which has higher earnings & valuation, BLTE or ATAI?

Which has more volatility & risk, BLTE or ATAI?

Does the media favor BLTE or ATAI?

Summary

How does Atai Beckley compare to Scholar Rock?

Do insiders and institutionals hold more shares of SRRK or ATAI?

Is SRRK or ATAI more profitable?

Which has higher valuation & earnings, SRRK or ATAI?

Which has more risk & volatility, SRRK or ATAI?

Does the media favor SRRK or ATAI?

Do analysts rate SRRK or ATAI?

Summary

How does Atai Beckley compare to Apogee Therapeutics?

Which has more risk and volatility, ATAI or APGE?

Do insiders and institutionals hold more shares of ATAI or APGE?

Is ATAI or APGE more profitable?

Do analysts prefer ATAI or APGE?

Which has higher valuation and earnings, ATAI or APGE?

Does the media refer more to ATAI or APGE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI vs. The Competition

Atai Beckley Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools